文献速递抗栓抗凝管理肝肾功能剂量调整药物相互作用

欧洲六国非瓣膜性房颤患者直接口服抗凝药使用发生率及用户特征(2008-2015):跨国药物利用研究

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study.
PubMed 文献 · Br J Clin Pharmacol · 2019-09-04

结果显示阿哌沙班和利伐沙班使用增加而达比加群减少,且患者特征(合并症、潜在相互作用药物、剂量调整)存在国家间差异。

要点

  • 达比加群和利伐沙班标准化年发生率分别为1.93-2.60/万和0.11-8.71/万(2011-2015)。
  • 阿哌沙班标准化年发生率为0.01-8.12/万(2012-2015)。

核心结论

  • 研究期内阿哌沙班和利伐沙班使用增加而达比加群减少。
  • 患者特征如合并症、潜在相互作用药物及剂量调整存在数据库间差异。

研究设计与样本

  • 纵向药物利用研究,2008年1月至2015年12月,采用共同方案。
  • 进行年度期间发生率及按年龄和性别的直接标准化。
  • 评估与年龄和肾功能变化相关的剂量调整及潜在相互作用药物联用。

主要发现

  • 2011-2015年达比加群标准化发生率为1.93-2.60/万。
  • 2011-2015年利伐沙班标准化发生率为0.11-8.71/万。
  • 2012-2015年阿哌沙班标准化发生率为0.01-8.12/万。
  • 2015年DOAC发生率从SIDIAP(西班牙)9/万到DNR(丹麦)28/万不等。
  • 心血管合并症比例从Mondriaan(荷兰)25.4%到AOK Nordwest(德国)82.9%不等。

关键数值与推荐

  • 仅DNR数据库覆盖总参考人群,其他数据库为人群代表性样本。
  • 数据库药物数据源类型(行政、临床)存在差异。
  • 剂量调整比例范围为4.6%(BIFAP,西班牙)至15.6%(EGB,法国)。
  • 潜在相互作用药物联用比例范围为16.4%(SIDIAP)至70.5%(EGB)。

临床怎么用

  • 临床应关注DOAC使用中的剂量调整(基于年龄和肾功能)。
  • 需评估并管理DOAC与潜在相互作用药物的联用。
  • 不同国家间患者合并症和用药特征存在差异,需结合本地数据个体化评估。

局限性

  • 数据库人群覆盖范围不一,仅DNR覆盖总参考人群。
  • 数据库药物数据源类型(行政、临床)存在差异。
  • 各数据库间患者特征(合并症、相互作用药物、剂量调整)存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries. METHODS: Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed. RESULTS: A total of 186 405 new DOAC users (age ≥18 years) were identified. Standardized incidences varied from 1.93-2.60 and 0.11-8.71 users/10 000 (2011-2015) for dabigatran and rivaroxaban, respectively, and from 0.01-8.12 users/10 000 (2012-2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10 000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only 1 database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP) and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany). CONCLUSION: Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as comorbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH).

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ibáñez L, Sabaté M, Vidal X, et al. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. Br J Clin Pharmacol. 2019. PMID: 31318059. doi:10.1111/bcp.14071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。